Sanofi

Name of the program: 
Sanofi Access to Medicines
Short description of the organization and its work to control and eliminate NTDs:

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

Sanofi is committed to the fight against neglected tropical diseases, particularly within the scope of a long-term partnership with the World Health Organization (WHO). Launched in 2001 with a program focused on sleeping sickness, the partnership was extended to include leishmaniasis, Buruli ulcer, yaws and Chagas disease. 

Since the beginning of this alliance, over 27 million people living in endemic areas in sub-Saharan Africa have been screened for sleeping sickness, and more than175,000 patients have received free treatment for a disease which is usually fatal if left untreated. Between 2001 and 2013, the number of new cases has also dropped by 77%. However as current treatments may be poorly tolerated and require several intravenous infusions, Sanofi, in partnership with the Drugs for Neglected Diseases initiative (DNDi), is working to develop a promising new oral treatment for sleeping sickness. All these initiatives aim to eliminate the disease by 2020. 

In 2012 and 2013, Sanofi, together with Eisai and the Bill and Melinda Gates Foundation, donated 120 million tablets of diethylcarbamazine citrate (DEC) to the WHO lymphatic filariasis elimination pogram, providing treatment for 30 million people. Sanofi has also entered into partnerships to screen molecules for activity on Chagas disease, leishmaniasis, lymphatic filariasis with the objective to develop new treatments for these NTDs.

Sanofi is one of the 20 original endorsers of the London Declaration